Grace Therapeutics (GRCE) Other financing activities (2019 - 2025)

Grace Therapeutics (GRCE) posted Other financing activities of $241000.0 for Q4 2025, up 502.5% sequentially from $40000.0 in Q1 2021.

Grace Therapeutics (GRCE) Other financing activities (2019 - 2025) Analysis & Trends

Grace Therapeutics has reported Other financing activities for 4 years, with the latest figure at $241000.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $241000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $241000.0 (changed N/A YoY) and the FY2026 annual result came in at $4.0 million, changed N/A from the prior year.
Other financing activities grew to $241000.0 in Q4 2025 per GRCE's latest filing, from $40000.0 in the prior quarter.
Over five years, Other financing activities peaked at $241000.0 in Q4 2025 and troughed at $40000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Grace Therapeutics	37.04 Mn	37.04 Mn	-

Download Data